Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate

International Journal of Cancer

Volumn 131, Issue 6, 2012, Pages

  Wang, Wei ^a   Hodkinson, Philip ^b   McLaren, Fiona ^b   MacKinnon, Alison ^b   Wallace, William ^b   Howie, Sarah ^b   Sethi, Tariq ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

cytokine; IL 15; small cell lung cancer; survival; Treg cell

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

AGED; ARTICLE; CANCER CELL; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FOXP3+ T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IN VITRO STUDY; LUNG BIOPSY; LUNG SMALL CELL CANCER; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; T LYMPHOCYTE;

CARCINOMA, SMALL CELL; CELL CYCLE; CELL LINE, TUMOR; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-15; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84864130225     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27613     Document Type: Article

References (39)

1. Rintoul RC, Sethi T,. The role of extracellular matrix in small-cell lung cancer. Lancet Oncol 2001; 2: 437-42.
2. Oze I, Hotta K, Kiura K, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009; 4: e7835.
3. Darnell RB, DeAngelis LM,. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341: 21-2.
4. Nakamura H, Saji H, Ogata A, et al. Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 2002; 37: 161-9.
5. Johnston-Early A, Cohen MH, Fossieck BE Jr, et al. Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer 1983; 52: 1395-400.
6. Moriya K, Wakabayashi A, Shimizu M, et al. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells. Cancer Immunol Immunother 2010; 59: 1083-95.
7. Schwartz-Albiez R, Monteiro RC, Rodriguez M, et al. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol 2009; 158 (Suppl 1): 43-50.
8. Nanni P, Nicoletti G, Palladini A, et al. Antimetastatic activity of a preventive cancer vaccine. Cancer Res 2007; 67: 11037-44.
9. Goldstein DJ, Austin JH, Zuech N, et al. Carcinoma of the lung after heart transplantation. Transplantation 1996; 62: 772-5.
10. Stebbing J, Duru O, Bower M,. Non-AIDS-defining cancers. Curr Opin Infect Dis 2009; 22: 7-10.
11. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-68.
12. Zhou L, Chong MM, Littman DR,. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009; 30: 646-55.
13. Banham AH, Powrie FM, Suri-Payer E,. FOXP3+ regulatory T cells: current controversies and future perspectives. Eur J Immunol 2006; 36: 2832-6.
14. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693-700.
15. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-11.
16. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010; 184: 3433-41.
17. Gottschalk RA, Corse E, Allison JP,. Expression of helios in peripherally induced foxp3+ regulatory T cells. J Immunol 2012; 188: 976-80.
18. Akimova T, Beier UH, Wang L, et al. Helios expression is a marker of T cell activation and proliferation. PLoS One 2011; 6: e24226.
19. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-72.
20. Ladanyi A, Mohos A, Somlai B, et al. FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma. Pathol Oncol Res 2010; 16: 303-9.
21. Sorrentino C, Musiani P, Pompa P, et al. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res 2011; 17: 1571-81.
22. Winerdal ME, Marits P, Winerdal M, et al. FOXP3 and survival in urinary bladder cancer. BJU Int 2011; 108: 1672-8
23. Lee WS, Park S, Lee WY, et al. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 2010; 116: 5188-99.
24. Mougiakakos D, Johansson CC, Trocme E, et al. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2- positive uveal melanoma. Cancer 2010; 116: 2224-33.
25. Shen Z, Zhou S, Wang Y, et al. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol 2010; 136: 1585-95.
26. Xia J, Liu W, Hu B, et al. IL-15 promotes regulatory T cell function and protects against diabetes development in NK-depleted NOD mice. Clin Immunol 2010; 134: 130-9.
27. Imamichi H, Sereti I, Lane HC,. IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3. Eur J Immunol 2008; 38: 1621-30.
28. Motohashi S, Nakayama T,. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 2008; 99: 638-45.
29. Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13: 98-107.
30. Dudley ME, Gross CA, Langhan MM, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010; 16: 6122-31.
31. Rowley J, Monie A, Hung CF, et al. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor β/common γ signaling in trans. J Immunol 2008; 181: 8237-47.
32. Casetti R, Agrati C, Wallace M, et al. Cutting edge: TGF-β1 and IL-15 induce FOXP3+ γδ regulatory T cells in the presence of antigen stimulation. J Immunol 2009; 183: 3574-7.
33. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 1994; 264: 965-8.
34. Podolsky DK,. Healing the epithelium: solving the problem from two sides. J Gastroenterol 1997; 32: 122-6.
35. Waldmann TA,. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
36. Badolato R, Ponzi AN, Millesimo M, et al. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood 1997; 90: 2804-9.
37. Jakobisiak M, Golab J, Lasek W,. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 2011; 22: 99-108.
38. Lindqvist CA, Christiansson LH, Thorn I, et al. Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology 2011; 133: 296-306.
39. Correale P, Rotundo MS, Del Vecchio MT, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010; 33: 435-41.